Blepharitis

Phacoemulsification is a common cataract surgery performed under topical anesthesia, which is generally safe but can cause pain, anxiety, and discomfort for some patients. This research evaluates the effect of oral anti-anxiety medication, specifically Alprazolam, on improving patient satisfaction during second eye cataract surgery. The study aims to clarify whether oral sedation can reduce pain, anxiety, and side effects like nausea and dizziness compared to no sedation during phacoemulsification. Patients will receive either a single oral dose of Alprazolam or a placebo tablet 30 minutes before surgery. The dose of Alprazolam is 0.5 mg for most patients, with a reduced 0.25 mg dose for those over 65 years or with liver disease. The study compares these groups to assess how oral sedation affects anxiety, pain, and surgical satisfaction. This is an extension study involving patients undergoing surgery on their second eye with topical anesthesia. During the trial, participants will complete questionnaires assessing pain, anxiety, and overall satisfaction before and after surgery. Researchers will monitor intraoperative discomfort and postoperative anxiety levels. Data from approximately 250 patients will be collected and analyzed for these outcomes. This study runs from March 2025 to December 2027, focusing on improving cataract surgery experiences safely and conveniently.

This research aims to analyze videodermatoscopic features of neoformations located in and around the eye, including ocular, periocular, conjunctival, and eyelid areas. It uses advanced videodermatoscopy technology to closely examine these lesions, assessing characteristics like size, shape, color, and internal structure. The goal is to help differentiate benign neoformations from those that may need further diagnosis or treatment. Participants with various ocular and periocular neoformations such as melanocytic nevus, seborrheic keratosis, angioma, basal cell carcinoma, melanoma, and others will be observed. This is an observational study without drug or device interventions. The analysis focuses on monitoring features that could suggest whether the neoformations are benign or malignant from enrollment until the end of 2026. During the study, participants will undergo detailed videodermatoscopic examinations to collect data on the lesions. Researchers will evaluate the features of these neoformations over time to distinguish their nature. The study involves regular assessments and does not include treatment. Participation may last up to several years to monitor lesion characteristics and outcomes.

Researchers are developing and managing the AnovaOS Network Powered Patient Registry to collect real-world patient data across various diseases globally. This registry aims to capture meaningful clinical information on diagnosis, infection course, treatments, and outcomes to enhance understanding and support future clinical trials and observational studies. The registry serves as a resource to better understand, prevent, diagnose, and treat diverse health conditions. Participants' data will be gathered through this registry, which can also be used to recruit individuals for clinical trials and observational studies on promising therapies. The registry collects ongoing information on patients' health status and treatments, enabling long-term monitoring and analysis. This observational study does not involve administering treatments but focuses on data collection and management. Participants will provide information through questionnaires or instruments, either personally or via an informed proxy, with an expected follow-up once per year. The research team will assess natural history, clinical effectiveness, safety, and quality of care over a period of five years. The registry includes patients with a wide range of conditions, and participation requires informed consent and the ability to complete follow-up data collection.

Researchers are evaluating eyelid conditions using deep learning methods to automatically analyze eyelid shape and blinking patterns. The study aims to measure features like margin reflex distance, eyelid contour, corneal exposure area, and blinking frequency, velocity, and duration. It also seeks to predict different types of levator muscle function based on blinking characteristics. This observational research involves people with various eyelid diseases as well as normal volunteers. Participants include normal individuals and patients with blepharoptosis, blepharospasm, dry eye disease, or Graves' disease. Facial photographs and blinking videos are collected to capture eyelid topology and kinetics. These images and videos are then analyzed using deep learning techniques to extract one-dimensional and two-dimensional eyelid parameters and to classify levator muscle function subtypes. Throughout the study, which lasts up to 5 years, researchers will monitor eyelid features and blinking behavior using the collected visual data. The primary outcomes include detailed measures of eyelid shape and function assessed continuously during the study period. This long-term observation will help improve understanding of eyelid diseases and develop new methods for their assessment.

Researchers are studying the use of scleral lenses for patients with irregular corneal astigmatism caused by various ocular surface diseases. This prospective clinical study focuses on how scleral lenses may improve vision clarity, comfort, and patient satisfaction. Patients with corneal irregularities from conditions like post-keratoconus surgery, post-keratoplasty, or trauma are enrolled to assess these lenses' effects. Participants are divided into two groups: one group will wear scleral lenses while the other group will not receive this treatment. The study includes comprehensive eye exams, such as corneal topography, visual acuity testing, and tear film analysis. Those fitted with scleral lenses are followed up at one week, one month, and three months after fitting to evaluate lens success and comfort. Throughout the study, participants undergo vision tests and complete comfort questionnaires. The main measurement is scleral lens fitting success assessed four hours after application, along with subjective comfort evaluations. Researchers compare vision and comfort before and after lens use. The study spans from initial assessment through three months of follow-up to monitor outcomes and satisfaction.

Researchers are studying the relationship between clinical factors and the occurrence of adverse drug reactions in hospitalized patients who receive tropicamide/phenylephrine 8 mg/50 mg/mL. This study aims to identify which clinical determinants may increase the risk of these reactions and provide safety information for this commonly used ophthalmic drug combination. It also seeks to establish safety measures for patients undergoing eye examinations or surgery where these drugs are used. The study involves hospitalized patients scheduled for surgery who will receive two drops of tropicamide/phenylephrine 8 mg/50 mg/mL. Vital signs will be measured before administration and then at several time points afterward, including 5, 15, 30 minutes, and 1, 2, and 3 hours post-administration. Data will be collected using questionnaires and analyzed to find associations between clinical factors and adverse reactions. Participants will be monitored closely through vital sign checks and questionnaires during the study period. Researchers will evaluate adverse drug reactions and clinical determinants to understand their connection. The main outcome is to assess vital signs at set intervals following drug administration and identify any adverse reactions. The study is observational and aims to enhance the safety profile of this medication in hospitalized patients.

This research aims to develop and test a practical model for remote eye care consultation using vision self-testing. It focuses on overcoming barriers faced by patients, clinicians, and the healthcare system when adopting remote consultations, especially issues related to technology trust and visual acuity assessments. The study is observational and involves collaboration between patients, the public, and NHS staff to create a sustainable and inclusive solution. The study uses an innovative approach with the DigiVis app for vision self-testing during remote consultations. It takes place in three diverse NHS eye departments and involves co-designing the implementation model with stakeholders. Patients are assigned to the remote consultation pathway by their clinicians. The model will be evaluated before, during, and after 14 months of operation, including questionnaires completed online by both patients and staff to assess their experiences and attitudes. Participants will complete online questionnaires before and after their remote consultation to measure their views on the e-health technology, while staff will complete surveys to assess how well the technology is integrated into routine practice. The main outcomes include changes in patient perceptions and staff normalization of the technology over 30 months. The study will also collect qualitative data from interviews and focus groups to understand challenges and support model improvements. The overall participation duration can last up to 30 months including follow-up assessments.

Researchers are evaluating the effects of Acoltremon ophthalmic solution 0.003% on tear production in patients with Stage 1 Neurotrophic Keratopathy, a condition where corneal tissue breakdown reduces tear production and nerve function. This Phase 4 study aims to gather clinical data on how this treatment may improve wound healing and nerve regeneration in the cornea. Participants will receive Acoltremon eye drops twice daily in both eyes for 8 weeks. If both eyes qualify, the eye with worse vision will be studied. This open-label trial monitors changes in tear production and visual acuity over the treatment period. Participants who do not respond well may be switched to standard care treatments. During the study, participants will be assessed for tear production using the unanesthetized Schirmer test at baseline and after 8 weeks. Visual acuity and corneal staining will also be evaluated. Safety is monitored throughout. The total participation lasts 8 weeks, with careful follow-up to measure changes in ocular surface disease signs and symptoms.

This research aims to compare the effectiveness and safety of two concentrations of sevoflurane inhalation (6% and 8%) for anesthesia induction in children aged 1 to 6 years undergoing minor ophthalmic surgery, such as chalazion excision. The study is a randomized controlled trial focusing on pediatric patients with a physical status classified as ASA I and suitable for inhalation anesthesia. Participants will be randomly assigned to receive either 6% or 8% sevoflurane inhalation through a face mask for anesthesia induction. Both groups will undergo general anesthesia maintained with sevoflurane during the minor eye surgery. The study measures include the Pediatric Anesthesia Emergence Delirium (PAED) scale, along with other parameters such as induction and recovery times, hemodynamic monitoring, and perioperative respiratory events. Throughout the trial, participants will be closely monitored for emergence agitation within 30 minutes after recovery, as well as for adverse events such as respiratory depression, hypoxia, coughing, nausea, and vomiting. Researchers will also record induction and recovery times immediately following anesthesia administration and discontinuation. Study participation involves careful evaluation and monitoring to assess the safety and effects of the two sevoflurane concentrations during the surgical procedure and recovery period.

Dry eye syndrome affects about 10 to 20% of people worldwide, with meibomian gland dysfunction (MGD) being a common cause. MGD occurs when the small glands in the eyelids that produce oils for the tear film become blocked or change, leading to faster tear evaporation and symptoms like eye irritation and inflammation. This study is evaluating whether thermal therapy using the MiBo Thermoflo device works better than the standard treatment of warm compresses and eyelid massage for dry eye caused by MGD. Participants will be randomly assigned to one of two treatment groups to compare these approaches over 24 weeks. One group will receive three sessions of thermal therapy with the MiBo Thermoflo device, each session 11 minutes per eye, spaced two weeks apart. The other group will use warm compresses and perform eyelid massage twice daily for 11 minutes per eye. Both groups will continue their usual dry eye care as needed during the study period. This design allows researchers to assess differences in treatment effects over time. Participants will be followed for 24 weeks, during which various eye health measures will be regularly checked. These include tests of gland function, tear quality and stability, eye surface staining, symptom questionnaires, and tear composition. Researchers will monitor safety and any adverse events throughout the study. The goal is to see if thermal therapy provides better relief and improvement compared to traditional warm compresses and massage therapy.